|
"greig nh"的相关文件
显示项目 1-10 / 19 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2025-03-17 |
3-Monothiopomalidomide, a new immunomodulatory imide drug (IMiD), blunts inflammation and mitigates ischemic stroke in the rat
|
Chen, KY;Hsueh, SC;Parekh, P;Batsaikhan, B;Tweedie, D;Luo, WM;Patel, C;Chiang, YH;Bambakidis, N;Hoffer, BJ;Huang, CZ;Yu, SJ;Wu, KJ;Wang, Y;Hong, EJ;Kim, DS;Greig, NH |
| 國家衛生研究院 |
2024-04-04 |
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease
|
Yu, SJ;Wang, Y;Shen, H;Bae, EK;Li, YZ;Sambamurti, K;Tones, MA;Zaleska, MM;Hoffer, BJ;Greig, NH |
| 國家衛生研究院 |
2024-03-27 |
Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: Relevance for neurodegenerative disorders
|
Li, Y;Vaughan, KL;Wang, Y;Yu, SJ;Bae, EK;Tamargo, IA;Kopp, KO;Tweedie, D;Chiang, CC;Schmidt, KT;Lahiri, DK;Tones, MA;Zaleska, MM;Hoffer, BJ;Mattison, JA;Greig, NH |
| 國家衛生研究院 |
2020-08-11 |
PT320, sustained-release exendin-4, mitigates L-DOPA-Induced dyskinesia in a rat 6-Hydroxydopamine model of Parkinson’s disease
|
Yu, SJ;Chen, S;Yang, YY;Glotfelty, EJ;Jung, J;Kim, HK;Choi, HI;Choi, DS;Hoffer, BJ;Greig, NH;Wang, Y |
| 國家衛生研究院 |
2020-02-21 |
Post-treatment with posiphen reduces endoplasmic reticulum stress and neurodegeneration in stroke brain
|
Yu, SJ;Wu, KJ;Bae, E;Wang, YS;Chiang, CW;Kuo, LW;Harvey, BK;Greig, NH;Wang, Y |
| 國家衛生研究院 |
2019-08 |
Pifithrin-alpha reduces methamphetamine neurotoxicity in cultured dopaminergic neurons
|
Chen, YH;Bae, E;Chen, H;Yu, SJ;Harvey, BK;Greig, NH;Wang, Y |
| 國家衛生研究院 |
2018-10-19 |
Pomalidomide ameliorates H(2)O(2)-induced oxidative stress injury and cell death in rat primary cortical neuronal cultures by inducing anti-oxidative and anti-apoptosis effects
|
Tsai, YR;Chang, CF;Lai, JH;Wu, JC;Chen, YH;Kang, SJ;Hoffer, BJ;Tweedie, D;Luo, W;Greig, NH;Chiang, YH;Chen, KY |
| 國家衛生研究院 |
2018-07-16 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease
|
Chen, S;Yu, SJ;Li, Y;Lecca, D;Glotfelty, E;Kim, HK;Choi, HI;Hoffer, BJ;Greig, NH;Kim, DS;Wang, Y |
| 國家衛生研究院 |
2018-07-16 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease [Erratum: Scientific Reports. 2018 Jul 16;8:Article number 10722.]
|
Chen, S;Yu, SJ;Li, Y;Lecca, D;Glotfelty, E;Kim, HK;Choi, HI;Hoffer, BJ;Greig, NH;Kim, DS;Wang, Y |
| 國家衛生研究院 |
2017-09 |
A new treatment strategy for Parkinson's disease through the gut-brain axis: The glucagon-like peptide-1 receptor pathway
|
Kim, DS;Choi, HI;Wang, Y;Luo, Y;Hoffer, BJ;Greig, NH |
显示项目 1-10 / 19 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
